Clinical Trials Directory

Trials / Terminated

TerminatedNCT00458159

A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes

Status
Terminated
Phase
Phase 1
Study type
Interventional
Enrollment
34 (actual)
Sponsor
Celgene · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes.

Conditions

Interventions

TypeNameDescription
DRUGCC-11006Doses: 10mg, 15mg, 25mg, 35mg, \& 50mg, taken once daily, orally.

Timeline

Start date
2007-05-01
Primary completion
2008-10-01
Completion
2008-12-01
First posted
2007-04-09
Last updated
2019-12-13

Locations

7 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00458159. Inclusion in this directory is not an endorsement.